AbbVie Inc. is 198.7x more valuable than Aurinia Pharmaceuticals Inc. by market capitalization ($399.47 B vs $2.01 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AUPH | ABBV |
|---|---|---|
| Market cap | $2.01 B | $399.47 B |
| US-listed rank | #2095 | #28 |
| Revenue (latest FY) | $283.06M | $61.16B |
| Net income (latest FY) | $287.20M | $4.23B |
| Net margin | 101.5% | 6.9% |
| P/E (trailing FY) | 7.0 | 94.5 |
| SEC filings | 595 | 1,008 |
AbbVie Inc. is 198.7x more valuable than Aurinia Pharmaceuticals Inc. by market capitalization ($399.47 B vs $2.01 B).
In their latest fiscal years, Aurinia Pharmaceuticals Inc. reported $283.06M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Aurinia Pharmaceuticals Inc. and AbbVie Inc., or browse the full rankings.